Plasma PCSK9
Plasma PCSK9 concentrations during an oral fat load and after short term high-fat, high-fat high-protein and high-fructose diets
... in plasma PCSK9 upon a high-fructose diet are causative of the variations in VLDL-TG and what could be the molecu- lar mechanisms involved, in particular whether PCSK9 acts upon hepatic VLDL ...with ...
11
Relation of plasma PCSK9 levels to lipoprotein subfractions in patients with stable coronary artery disease
... that plasma PCSK9 levels were significantly and independently associ- ated with the cholesterol concentrations of intermediate and small LDL subfractions as well as mean LDL particle size in patients with ...
9
Impact of currently prescribed lipid-lowering drugs on plasma PCSK9 concentration: single or in combination study in rats
... that PCSK9 promotes the degradation of LDLR and could limit the beneficial ef- fects of lipid-lowering drugs ...elevate plasma PCSK9 concentrations and may have rapid impact on PCSK9 levels ...
6
Plasma PCSK9 levels are significantly modified by statins and fibrates in humans
... that plasma PCSK9 levels are sig- nificantly modified by two common lipid therapies; fibrates and statins (Tables 1 and 2 and Figs 1 and ...on plasma PCSK9 levels has not been previously ...of ...
9
Association of PCSK9 plasma levels with metabolic patterns and coronary atherosclerosis in patients with stable angina
... circulating PCSK9 levels, coronary disease and risk, is complex and might be par- tially independent of LDL ...cholesterol. PCSK9 plasma levels were associated with the severity of coronary lesions ...
12
In vivo genome and base editing of a human PCSK9 knock-in hypercholesterolemic mouse model
... human PCSK9 or mouse Pcsk9 showed that inhibition of the human but not the mouse gene was required to achieve an effect on cholesterol ...in plasma PCSK9 levels relative to the frequency of ...
14
Therapeutic effect of nanoliposomal PCSK9 vaccine in a mouse model of atherosclerosis
... anti- PCSK9 antibodies in vivo, plasma levels of PCSK9 in vaccinated mice were ...anti- PCSK9 antibody was found to specifically target plasma PCSK9 in hypercholesterolemic ...
15
An Anti-PCSK9 Antibody Reduces LDL-Cholesterol On Top Of A Statin And Suppresses Hepatocyte SREBP-Regulated Genes
... for PCSK9 The biological activity of 1B20 was examined using in vitro assays that measure PCSK9 ...measures PCSK9-dependent effects on cellular LDL-uptake, where LDL is fluorescently labeled ...
18
The elevation of plasma concentrations of apoB-48-containing lipoproteins in familial hypercholesterolemia is independent of PCSK9 levels
... in plasma apoB-48 levels. Moreover, the measurement of plasma PCSK9 by ELISA did not allowed to quantified the relative proportion of furin-cleaved, LDL-associated or free PCSK9 as well as the ...
8
Circulating PCSK9 affects serum LDL and cholesterol levels more than SREBP-2 expression
... between PCSK9 and cholesterol-related parameters especially the total cholesterol/HDL-C ratio (β = ...circulating PCSK9 and SREBP-2 expression levels (r = ...with plasma PCSK9 values, ...
5
Differential effects of PCSK9 loss of function variants on serum lipid and PCSK9 levels in Caucasian and African Canadian populations
... of plasma PCSK9 illuminates a dif- ference in the mechanism of action of the L10A53V vari- ation versus the I474V variation in lowering LDLC in our Caucasian ...if plasma PCSK9 levels decrease ...
11
Circulating PCSK9 levels and CETP plasma activity are independently associated in patients with metabolic diseases
... influence PCSK9 levels as an off-target ...decrease PCSK9 levels in humans [17] and in rhesus macaques ...the PCSK9 promoter ...hepatic PCSK9 expression by interacting with SREBP2, leading to ...
8
Potential of PCSK9 as a new target for the management of LDL cholesterol
... US Food and Drug Administration has recently asked for an assessment of potential neurocognitive side effects, such as memory loss and confusion, and a new larger trial is underway to provide a more definitive assessment ...
14
New developments in atherosclerosis: clinical potential of PCSK9 inhibition
... (B) PCSK9 (unbound PCSK9 or LDL-bound PCSK9) directly binds the eGF-A domain of LDLR and targets LDLR toward intracellular degradation through an endosomal/lysosomal ...route. PCSK9 half-life ...
9
Decreased PCSK9 expression in human hepatocellular carcinoma
... of PCSK9 in HCC, because PCSK9 is known to stimulate liver regeneration after partial hepatectomy [8] and plays an essential role in cholesterol ...immunohistochemistry, PCSK9 was much less present ...
10
Regulation of hepatic LDL receptors by mTORC1 and PCSK9 in mice
... in plasma cholesterol levels (Figure 3, A and B), whereas there was no significant change in the mRNA levels of Ldlr, Srebp-2, or its target genes (Supplemental Fig- ure ...of PCSK9 and LDLR by insulin ...
10
PCSK9 inhibition: the way forward in the treatment of dyslipidemia
... whom PCSK9 inhibition would be first ...from PCSK9 inhibition con- sists of those remaining at increased risk of CVD despite currently available lipid-lowering treatment due to, for example, having a very ...
6
PCSK9 inhibition in the management of hyperlipidemia: focus on evolocumab
... Inhibiting PCSK9 results in improved LDLR recycling, increased LDLR availability on hepatocyte cell surfaces, and reduced blood LDL-C levels, making PCSK9 inhibition a novel therapeutic strategy for ...
13
IDENTIFICATION OF POTENTIAL INHIBITORS FOR LOWERING CHOLESTEROL LEVEL BY INHIBITING PCSK9
... Methods: Known inhibitors for the PCSK9 protein were taken from the BINDING database. Molecular docking was performed for the known inhibitors with the PCSK9 protein. After docking, the best inhibitor was ...
5
Development of proprotein convertase subtilisin/kexin type 9 inhibitors and the clinical potential of monoclonal antibodies in the management of lipid disorders
... as PCSK9 inhibitors is under progress by a few pharmaceutical companies (Pfizer, Seromatrix and ...of PCSK9 inhibitors will be a welcome addition to anti-lipid ...
13